MTOR and neoplasm: Lastly, treatment of the Kras/Lkb1 GEMMs with the multi-target receptor tyrosine kinase inhibitor sunitinib (Sutent) was effective and reduced tumour size, increased tumour necrosis and slowed tumour progression in primary lesions demonstrating that receptor tyrosine kinases may be targeted in addition to the PI3K/mTOR pathway (Gandhi et al, 2009).